The potential for IMUN is exponential. However. I have had many concerns with this stock. First; their vow to keep shareholders informed....they are not doing that. Second; the continued dumping off of stock at well under the ask price, and the deliberate drive down of stock price. Third; the internal issues with CEO Noreen Grffin. Fourth; many years of failure in Africa to require the necessary approvals in Africa with all agencies that need to be involved in this approval. Research is the cornerstone of any legal transaction. Whether it be for a business, taxes, goverment approvals, a courtroom, etc. It has been years, and the CEO, and Board members in charge of getting this drug to the people who need it, have continued to fail to get the required documents in play in Africa. This is nothing short of incompetence. My last issue with IMUN, is there absolute lack of concern for their shareholders, not only with the failure of decimination of information, but in responding to individual shareholders. This company has been around for quite a few years, and no email for shareholders to contact? I called the number on their website, they referred me to another number for investor relations. I called that number, someone answered: hello. Did not say they were with IMUN Therapeutics of anything, no professionalism. They had no information, nothing. They said they knew nothing. This was of great concern. I had a question for one of my Marijuana stocks, CLSH, and one of the board members returned my call and answered all my questions. That is the way a company should treat their shareholders. I am in for the long at this point, but I must be honest, if I was not invested so much at this point, I do not think I would be investing in IMUN now. The leadership at this company treats its shareholders the way Wal-Mart treated it's employees until a few years ago.